Corbus Pharmaceuticals Holdings, Inc.: 10-Q filed 2023-11-07

Name: Corbus Pharmaceuticals Holdings, Inc.: 10-Q filed 2023-11-07
Creator: Corbus Pharmaceuticals Holdings, Inc.

What Corbus Pharmaceuticals Holdings, Inc. reported in its quarterly report filed 2023-11-07 (fiscal Q3 2023): 44 published measures, 118 facts as tagged in accession 0000950170-23-060377.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-07
Fiscal period: fiscal Q3 2023
Accession: 0000950170-23-060377 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Corbus Pharmaceuticals Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	36,283,405	USD
At 2022-12-31	66,311,940	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	35,972,389	USD
At 2022-12-31	33,321,923	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	311,016	USD
At 2023-06-30	9,520,586	USD
At 2022-12-31	32,990,017	USD
At 2022-09-30	41,946,110	USD
At 2022-06-30	49,469,858	USD
At 2021-12-31	69,108,027	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-09-30	11,248,806	USD
At 2022-12-31	17,002,715	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,053,269	USD	92
2023-01-01 to 2023-09-30	-36,581,922	USD	273
2022-07-01 to 2022-09-30	-8,781,720	USD	92
2022-01-01 to 2022-09-30	-31,467,850	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-30,091,600	USD	273
2022-01-01 to 2022-09-30	-30,089,450	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	13,449	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-915,824	USD	273
2022-01-01 to 2022-09-30	-767,937	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	25,253,515	USD	273
2022-01-01 to 2022-09-30	18,294,400	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-428,662,589	USD
At 2022-12-31	-392,080,667	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	4,423,617	shares	92
2023-01-01 to 2023-09-30	4,295,178	shares	273
2022-07-01 to 2022-09-30	4,170,881	shares	92
2022-01-01 to 2022-09-30	4,170,466	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	4,423,617	shares	92
2023-01-01 to 2023-09-30	4,295,178	shares	273
2022-07-01 to 2022-09-30	4,170,881	shares	92
2022-01-01 to 2022-09-30	4,170,466	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2.27	USD/shares	92
2023-01-01 to 2023-09-30	-8.52	USD/shares	273
2022-07-01 to 2022-09-30	-2.11	USD/shares	92
2022-01-01 to 2022-09-30	-7.55	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2.27	USD/shares	92
2023-01-01 to 2023-09-30	-8.52	USD/shares	273
2022-07-01 to 2022-09-30	-2.11	USD/shares	92
2022-01-01 to 2022-09-30	-7.55	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-09-30	1,120,793	USD
At 2022-12-31	1,613,815	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	2,670,977	USD	273
2022-01-01 to 2022-09-30	4,450,361	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-9,487,938	USD	92
2023-01-01 to 2023-09-30	-34,973,954	USD	273
2022-07-01 to 2022-09-30	-8,181,456	USD	92
2022-01-01 to 2022-09-30	-29,038,625	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	31,205,973	USD
At 2022-12-31	60,181,102	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	31,542,328	USD
At 2022-12-31	12,639,938	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	4,713,532	USD
At 2022-12-31	2,173,963	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	9,487,938	USD	92
2023-01-01 to 2023-09-30	34,973,954	USD	273
2022-07-01 to 2022-09-30	8,181,456	USD	92
2022-01-01 to 2022-09-30	29,038,625	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	6,550,496	USD	92
2023-01-01 to 2023-09-30	24,187,544	USD	273
2022-07-01 to 2022-09-30	4,108,190	USD	92
2022-01-01 to 2022-09-30	9,894,068	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	4,423,683	shares
At 2022-12-31	4,171,297	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit	Days
At 2023-09-30	11,918,706	USD
At 2022-12-31	17,672,615	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	428,981,198	USD
At 2022-12-31	425,196,359	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-09-30	-8,035	USD
At 2022-12-31	-126,092	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-09-30	3,277,943	USD
At 2022-12-31	3,884,252	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-09-30	5,007,236	USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

Period	Value	Unit	Days
At 2023-09-30	20,025,456	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2023-09-30	4,528,546	USD
At 2022-12-31	4,707,038	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2023-09-30	3,407,753	USD
At 2022-12-31	3,093,223	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-09-30	201,271	USD
At 2022-12-31	155,346	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-09-30	44,410	USD
At 2022-12-31	22,205	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-09-30	7,545,781	USD
At 2022-12-31	5,999,252	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-09-30	2,280,255	USD
At 2022-12-31	791,616	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,053,269	USD	92
2023-01-01 to 2023-09-30	-36,581,922	USD	273
2022-07-01 to 2022-09-30	-8,781,720	USD	92
2022-01-01 to 2022-09-30	-31,467,850	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,037,516	USD	92
2023-01-01 to 2023-09-30	-36,463,865	USD	273
2022-07-01 to 2022-09-30	-8,869,274	USD	92
2022-01-01 to 2022-09-30	-31,612,279	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,937,442	USD	92
2023-01-01 to 2023-09-30	10,786,410	USD	273
2022-07-01 to 2022-09-30	4,073,266	USD	92
2022-01-01 to 2022-09-30	14,144,557	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	152,809	USD	92
2023-01-01 to 2023-09-30	493,022	USD	273
2022-07-01 to 2022-09-30	190,795	USD	92
2022-01-01 to 2022-09-30	578,598	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	217,545	USD	92
2023-01-01 to 2023-09-30	629,709	USD	273
2022-07-01 to 2022-09-30	77,712	USD	92
2022-01-01 to 2022-09-30	-324,322	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-565,331	USD	92
2023-01-01 to 2023-09-30	-1,607,968	USD	273
2022-07-01 to 2022-09-30	-600,264	USD	92
2022-01-01 to 2022-09-30	-2,429,225	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	1,986,399	USD	273
2022-01-01 to 2022-09-30	1,407,208	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	244,105	USD	273
2022-01-01 to 2022-09-30	0	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	2,527,083	USD	273
2022-01-01 to 2022-09-30	-1,237,294	USD	273

Inspect the source

Entity: Corbus Pharmaceuticals Holdings, Inc. / CIK 0001595097
Captured: 2026-09-20T09:24:35.285Z
SEC response SHA-256: 946cd75b294f9564550986f5a835381ea0b20b9b7c1140d70659a5c384e7d54a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001595097.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))